Status:
COMPLETED
Immune Changes in Severe COVID-19 Pulmonary Infections
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
SARS-CoV-2
Immune System Disorder
Eligibility:
All Genders
18+ years
Brief Summary
SARS-CoV-2 outbreak causes a spectrum of clinical patterns that varies from asymptomatic infection to mildly symptomatic manifestations and more-severe forms that need intensive care. Until now, the i...
Detailed Description
The most severe form of COVID-19 treated in intensive care for acute respiratory failure may have a poor prognosis. Both the level of IL-6 and the severity of the lymphopenia have been associated to t...
Eligibility Criteria
Inclusion
- confirmed COVID-19
- a positive RT- PCR,
- a highly suggestive thoracic CTScan,
- severe hypoxemia
Exclusion
- none
Key Trial Info
Start Date :
March 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04386395
Start Date
March 30 2020
End Date
June 30 2021
Last Update
July 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire NANCY
Vandœuvre-lès-Nancy, France, 54511